NeuroSense Therapeutics Ltd.
NRSN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875091
No open-market purchases or sales by NeuroSense Therapeutics Ltd. insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $285.7K in total; no superinvestor holds it.
Other share classesNRSNW
Q1 2026 vs. Q4 2025
How the institutions holding NeuroSense Therapeutics Ltd. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 13 | 13 | 0 |
| Shares | 346.1K | 379.7K | +33.6K (+9.7%) |
| Value | $266.2K | $286.7K | +$20.5K (+7.7%) |
New holders (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Independent Advisor Alliance | 50,000 | $37.8K | 0.00% |
| Jane Street Group, LLC | 28,670 | $21.6K | 0.00% |
| The PNC Financial Services Group, Inc. | 21,150 | $16.0K | 0.00% |
Sold out (3)
Institutions that held NeuroSense Therapeutics Ltd. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| GTS Securities LLC | 35,753 | $27.5K |
| Squarepoint Ops LLC | 17,926 | $13.8K |
| Jessup Wealth Management, Inc | 500 | $385 |